PMV Pharmaceuticals reports Q2 EPS (41c), consensus (38c)

Cash, cash equivalents, and marketable securities of $148.3 million as of June 30, 2025, providing expected cash runway to end of 2026. “Our team has continued to execute at an exceptionally high level as we advance the registrational Phase 2 PYNNACLE clinical trial,” said David Mack, Ph.D., President and Chief Executive Officer of PMV Pharma. “We look forward to providing data from the interim analysis on September 10.”